Arachidonic acid release from rat Leydig cells: the involvement of G protein, phospholipase A2 and regulation of cAMP production

A M Ronco, P F Moraga and M N Llanos

Unidad de Hormonas y Receptores, INTA, Universidad de Chile, Casilla 138-11, Santiago, Chile

(Requests for offprints should be addressed to A M Ronco; Email: amronco@uec.inta.uchile.cl)

Abstract

We have previously demonstrated that the release of arachidonic acid (AA) from human chorionic gonadotropin (hCG)-stimulated Leydig cells occurs in a dose- and time-dependent manner. In addition, the amount of AA released was dependent on the hormone–receptor interaction and the concentration of LH–hCG binding sites on the cell surface. The present study was conducted to evaluate the involvement of phospholipase A2 (PLA2) and G proteins in AA release from hormonally stimulated rat Leydig cells, and the possible role of this fatty acid in cAMP production. Cells were first prelabelled with $[^{14}C]$AA to incorporate the fatty acid into cell phospholipids, and then treated in different ways to evaluate AA release. hCG (25 mIU) increased the release of AA to 180 ± 12% when compared with AA released from control cells, arbitrarily set as 100%. Mepacrine and para-bromophenacyl bromide (pBpB), two PLA2 inhibitors, decreased the hormone-stimulated AA release to 85 ± 9 and 70 ± 24% respectively. Conversely, melittin, a PLA2 stimulator, increased the release of AA up to 200% over control. The inhibitory effect of mepacrine on the release of AA was evident in hCG-treated Leydig cells, but not in the melittin-treated cells. To determine if the release of AA was also mediated through a G protein, cells were first permeabilized and subsequently treated with pertussis toxin or GTPγS, a non-hydrolyzable analog of GTP. Results demonstrate that GTPγS was able to induce a similar level of the release of AA as hCG. In addition, pertussis toxin completely abolished the stimulatory effect of hCG on the release of AA, indicating that a member of the Gs family was involved in the hCG-dependent release of AA. Cells treated with PLA2 inhibitors did not modify cAMP production, but exogenously added AA significantly reduced cAMP production from hCG-treated Leydig cells, in a manner dependent on the concentration of AA and hCG. Results presented here suggest an involvement of PLA2 and G proteins in the release of AA from hCG-stimulated Leydig cells, and under particular conditions, regulation of cAMP production by this fatty acid in these cells.

Journal of Endocrinology (2002) 172, 95–104

Introduction

Activation and regulation of Leydig cell function is exerted primarily by luteinizing hormone (LH) or its analogue, human chorionic gonadotropin (hCG). Both molecules interact with membrane LH–hCG receptors, activating the classic second messenger, cAMP (Catt et al. 1980). However, additional second messengers such as calcium and chloride ions, and arachidonic acid (AA) or its metabolites, have also been involved in the regulation of steroidogenesis (Sullivan & Cooke 1986, Choi & Cooke 1990, Cooke et al. 1991). Several reports have indicated an important role for AA in the modulation of hormone-induced steroid production in rat Leydig cells (Cooke et al. 1991, Moraga et al. 1997, Wang et al. 1999). In these cells, a rapid release of AA has been detected after stimulation by LH (Cooke et al. 1991). We have demonstrated that AA release occurred in a dose- and time-dependent manner in hCG-stimulated Leydig cells. Furthermore, the release of AA was dependent on the hormone–receptor interaction and the concentration of LH–hCG binding sites on the cell surface (Moraga et al. 1997). AA may be released after hormone–receptor interaction, mainly by the action of phospholipase A2 (PLA2) or phospholipase C (PLC) and diacylglycerol lipase. In addition, AA can be metabolized by three independent pathways (cyclo-oxygenase, lipoxygenase and the cytochrome P450-dependent epoxygenase; Needleman et al. 1986), producing metabolites able to regulate LH and LH releasing hormone (LHRH)-induced testosterone production by rat Leydig cells (Didolkar & Sundaram 1987, Romanelli et al. 1995, Mele et al. 1997).

The role of AA in trophic hormone-stimulated steroid production in various steroidogenic cells has been well documented (Yamazaki et al. 1996, Abayasekara et al. 1990, Cooke et al. 1991, Boone et al. 1993, Moraga et al. 1997). Recently, in MA–10 mouse Leydig tumor cells, it
was demonstrated that AA is essential for steroidogenic acute regulatory (StAR) protein expression at the level of gene transcription (Wang et al. 2000). Moreover, the AA-mediated signal transduction pathway was different from the previously reported cAMP–protein kinase A–phosphorylation pathway (Wang & Stocco 1999). Recent results have shown that AA modulates the GTPase activity of G proteins, maintaining Gt proteins in their activated state, which in turn inhibits adenylate cyclase, which results in a decrease in cAMP concentrations (Marinero et al. 2000). All these results demonstrate that AA is involved in trophic hormone–stimulated steroid production in Leydig cells. At present, however, mechanisms involved in the release of AA from plasma membrane of hormonally stimulated Leydig cells are not completely understood. Therefore, the aim of this study was to evaluate the possible involvement of PLA2 and G proteins in the release of AA by hCG-stimulated rat Leydig cells, and the possible role of this fatty acid in cAMP production.

The present study provides evidence indicating that molecules able to modulate PLA2 activity and G proteins also regulate the release of AA from hCG-stimulated Leydig cells. Moreover, when hCG-stimulated release of AA is inhibited in the presence of PLA2 inhibitors, cAMP production is not modified. Nevertheless, in the presence of exogenously added AA, hCG-stimulated cAMP production is inhibited in a manner dependent on the concentrations of both hCG and AA. These results suggest an involvement of PLA2 and G proteins in the release of AA from hCG-stimulated Leydig cells. In addition, although cAMP production may occur independently of AA release in hormonally stimulated cells, the fatty acid may be able to modulate cAMP production under conditions exceeding a threshold of intracellular AA concentration. In summary, this study provides evidence for a mechanism of the release of AA in hCG-stimulated rat Leydig cells and the possible involvement of this fatty acid in modulation of cAMP production.

Materials and Methods

Materials
Human chorionic gonadotrophin (hCG, CR127) was generously donated by the NIHPP (USA). Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Gibco (Paisley, Strathclyde, UK). Bovine serum albumin (fraction V BSA and fatty acid-free BSA), arachidonic acid (free acid, sealed ampoule), GDP, GTPγS, pertussis toxin (PTX), mepacrine, parabromophenacyl bromide (pBpB), melittin and Percoll were obtained from Sigma Chemical Co. (St Louis, MO, USA). The cAMP detection kit was purchased from Amersham International (Amersham, Bucks, UK). [14C]Arachidonic acid ([14C]AA, specific activity 55 mCi/mmol) was purchased from NEN (Boston, MA, USA). Collagenase was from Worthington Biochemical Co. (Freehold, NJ, USA). All other chemicals were of analytical grade.

Cell isolation and purification
Leydig cells were isolated from 200–300 g Wistar rats from our colony. All animals were cared for according to the guidelines from International Animal Care. Animals were anesthetized and killed by decapitation. The testes were then removed, decapsulated and subjected to enzymatic dispersion with collagenase (0·25 mg/ml) at 37 °C for 15 min in a shaking bath to obtain interstitial cells, as previously described (Ronco & Valladares 1993). Interstitial cells were then filtered through gauze to remove fragments of seminiferous tubules and purified through a density gradient as described before (Ronco & Valladares 1993). Briefly, interstitial cells were applied to a 26 ml linear 10–80% Percoll gradient in Hepes buffer, pH 7·4, and centrifuged at 800 g for 30 min. Gradient fractions (1 ml) were collected and fractions 20–26 were pooled (Hedger & Eddy 1986). Leydig cell number was established by the histochemical reaction for 3β-hydroxysteroid dehydrogenase (3β–HSD) (Steinberger et al. 1966). Cell viability was assessed by trypan blue exclusion and histochemical staining for diaphorase, as previously described (Aldred & Cooke 1983). Leydig cell purity and viability were at least 90%. Data obtained from experiments were normalized and expressed per 10^6 Leydig cells.

Incorporation of AA to membrane phospholipids
Approximately 2 × 10^6 Leydig cells were incubated with 0·2 µCi [14C]AA in 1 ml DMEM–0·1% BSA, pH 7·3, at 34 °C, under an atmosphere of 95% air–5% CO2, for 4 h. Cells were then collected and centrifuged at 800 g for 10 min. The cellular pellet was washed twice and incubated under different experimental conditions to assess [14C]AA release.

Release of AA from membrane phospholipids
AA release was measured from prelabelled cells, essentially as already described (Moraga et al. 1997). Aliquots of resuspended Leydig cells (2 × 10^6 cells/ml) were preincubated with 0·2 µCi/tube [14C]AA as described before. After 4 h, cells were collected and washed twice with 4 ml DMEM–0·5% fatty acid–free BSA to remove free [14C]AA, and incubated for 2 h with different treatments. Total [14C]AA release (intracellular and from the incubation medium) was determined by adding 2 ml cold methanol to the cell suspension, and samples were stored under N2 at −20 °C until required for analysis. [14C]AA was extracted from the methanol phase with a solvent mixture, added in the following order: 1 ml chloroform,
32 µl HCl (12·06 M), 20 µg cold AA (as a tracer), 1 ml chloroform, 1 ml KCl 0·5 M (Kamel & Kubajac 1988). The phases were separated by low-speed centrifugation, the final chloroform phase dried under N₂, and [¹⁴C]AA separated from other lipids by thin-layer chromatography (TLC) on silica-gel plates. The ascending chromatography was developed with a mixture of hexane–diethylether–acetic acid (65:35:4, v/v/v). The [¹⁴C]AA band was detected with iodine, scraped, and analyzed by liquid scintillation counting in a Beckman LS 5000 TD liquid scintillation spectrometer.

**Treatments with inhibitors and activators of PLA₂**

To determine if PLA₂ was involved in the release of AA, prelabelled cells were preincubated for 30 min in DMEM–0·5% fatty acid-free BSA in the presence of different inhibitors (10 µM mepacrine or pBpB) or activators (melittin, 10 µM) of PLA₂. After that period, cells were treated with hCG (25 mIU) and incubated for 2 h. To assess if the activator melittin was able to reverse the inhibition induced by mepacrine, cells were preincubated with the inhibitor for 30 min, and then melittin or hCG was added and the incubation proceeded for 2 h. Total [¹⁴C]AA released was determined as described.

**GTP₇S assays and toxin treatments**

For GTP assays, [¹⁴C]AA prelabelled cells were permeabilized with saponin (25 µg/ml) for 15 min at 37 °C. In multiple repetitions, this procedure resulted in 85–94% of permeabilized Leydig cells, as determined by trypan blue exclusion. Permeabilized cells were incubated in the presence of GTP₇S (100 µM), hCG (25 mIU) or GDP (100 µM) as previously described (Gaurisankar & Fox 1994). For PTX treatment, prelabelled and permeabilized cells were preincubated for 40 min with PTX (20 ng/ml), then hCG (25 mIU) was added and incubation continued for an additional 2 h. Total [¹⁴C]AA released was determined as described.

**cAMP assays**

Purified Leydig cells (2 × 10⁶) were preincubated for 30 min at 34 °C with DMEM–0·1% BSA under an atmosphere of 95% air–5% CO₂, then incubated with isobutylmethylxanthine (IBMX, 25 µM) in the presence or absence of hCG (5 or 25 mIU) and different concentrations of AA (1–100 µM). In additional experiments, cells were preincubated for 30 min in the presence of different concentrations of mepacrine or pBpB (0·1–10 µM) under an atmosphere of 95% air–5% CO₂. After 3 h of incubation, aliquots from the cell suspension were extracted for cAMP determination according to the manufacturer’s instructions. In brief, 200 µl of the reaction mixtures were mixed with 1 ml ethanol and centrifuged. The pellets were washed with a mixture of ethanol–H₂O (2:1, v/v), and the successive supernatants were collected, mixed, and finally evaporated under N₂ at 55 °C. Residues were analysed for cAMP content.

**Data analysis**

Results are presented as mean ± s.e.m. Statistical analyses were made with the non-parametric Friedman ANOVA and Kendall coefficient of concordance test (Statistica for Windows, Release 4·5 Statsoft, Inc. 1993). Significance was assumed at P ≤ 0·05.

**Results**

**Effect of PLA₂ inhibitors and activators on the release of AA**

To determine the role of PLA₂ on the release of AA, Leydig cells prelabelled with [¹⁴C]AA were treated with inhibitors of PLA₂ and then stimulated with hCG (25 mIU).

Generally, after 4 h of incubation with 0·2 µCi [¹⁴C]AA, a mean value of 0·054 µCi (s.e.m. < 10%), equivalent to 982 pmol, was incorporated into Leydig cell phospholipids. Radioactivity released from control untreated Leydig cells after 2 h of incubation reached a value of 6895 ± 659 d.p.m., equivalent to a mass of 56± 5·5·4 pmol of [¹⁴C]AA. Usually, the amount of AA released from control cells was arbitrarily set as 100 ± s.e.m. %. In the presence of hCG, the release of AA significantly increased, to 101·7 ± 12·4·pmol, equivalent to 180 ± 22% of the non-stimulated AA release (Fig. 1). However, hCG-stimulated AA release was completely inhibited by mepacrine and pBpB (85 ± 9% and 70 ± 24% respectively; Fig. 1). In addition, mepacrine and pBpB did not significantly affect the release of AA from non-stimulated cells (Fig. 1).

The effect of melittin, an activator of PLA₂, was also evaluated. A dose–response curve of AA release is depicted in Fig. 2, where it can be observed that concentrations greater than 0·5 µM melittin significantly stimulated the release of AA over that in control cells.

The effect of mepacrine on hCG or melittin-stimulated AA release was also examined. In the presence of 10 µM melittin, the release of AA was increased threefold (310 ± 21%). As previously shown, hCG was able to stimulate the release of AA significantly, but the percentage stimulation was lower than that obtained with melittin (198 ± 18%). Although mepacrine completely inhibited the stimulatory effect of hCG on the release of AA, no inhibitory effect on the release of AA was observed in melittin-treated cells (Fig. 3).

**GTP₇S and PTX**

To determine if the release of AA was mediated through a G protein, prelabelled Leydig cells were permeabilized...
with saponin to allow entry of GTP\(_\text{S}\), a non-hydrolyzable analog of GTP. It was shown that GTP\(_\text{S}\) induces the release of AA to a similar extent as hCG (Fig. 4). Furthermore, the effects of these stimuli were not additive. As expected, GDP was not able to stimulate the release of AA.

To evaluate the type of G protein involved in AA release, the effect of PTX on the release of AA was determined. It was observed that PTX-treated cells showed a marked inhibition of the hCG-stimulated release of AA (Fig. 5).

**AA and cAMP production**

The effects of exogenous AA on cAMP production stimulated by two doses of hCG are shown in Fig. 6. The exogenous addition of AA to suspensions of Leydig cells did not affect cAMP production in the absence of hCG. As expected, a low dose of hCG (5 mIU) increased the cAMP production slightly, but significantly. Under these conditions, the additional presence of exogenous AA (1–50 µM) did not modify cAMP production. Although 100 µM AA reduced the hCG-stimulated cAMP production, the amount of cAMP was still significantly greater than that produced by control cells (Fig. 6A).

Addition of a higher dose of hCG (25 mIU) approximately doubled the amount of cAMP produced by Leydig cells (Fig. 6B). However, when cAMP production was stimulated with the higher dose of hCG, the response to exogenous AA was clearly different. Doses of 25 µM or more of AA very significantly inhibited the amount of cAMP produced in those hCG-stimulated Leydig cells (Fig. 6B).

To study the effect of PLA\(_2\) inhibitors on cAMP production stimulated by hCG, Leydig cells were independently treated with mepracine and pBpB. Cells treated with mepracine (0.1–10 µM; Fig 7A) or pBpB (0.1–10 µM; Fig 7B) did not inhibit cAMP production in cells stimulated with a dose of 25 mIU hCG.

**Discussion**

AA is a known component of cell membrane phospholipids. Because it is released in response to a hormonal
Materials and Methods. $^{14}$C AA released from cells without any air diacylglycerol lipase, and followed by phosphatidic acid phosphohydrolase and finally, PLA1 followed by lyso-lipase (Graber et al. 1994). Previous reports have indicated a direct effect of LH (Cooke et al. 1991) and hCG (Moraga et al. 1997) on the release of AA in these cells. Specifically, our previous results demonstrated that the release of AA in hCG-treated rat Leydig cells occurred in a dose- and time-dependent manner (Moraga et al. 1997). In addition, the amount of AA released was dependent on the hormone-receptor interaction and the concentration of LH–hCG binding sites present on the cell surface (Moraga et al. 1997).

At present, however, mechanisms involved in the release of AA by Leydig cells are not completely understood. Previous studies have indicated a direct effect of LH (Cooke et al. 1991) and hCG (Moraga et al. 1997) on the taxi of inhibitors or activators of PLA2 indicate that PLA2 could be involved in hCG-induced AA release. Two different inhibitors of PLA2 having different modes of action were used: mepacrine, which interferes with the substrate–enzyme interaction and the concentration of PLA2 on the cell surface (Moraga et al. 1997).

Saturation, it is now included in the list of fatty acids having a role as a signalling molecule in different somatic cells (Yamazaki et al. 1996, Cooke et al. 1991, Naor 1991, Boone et al. 1993, Gaurisankar & Fox 1994, Xing et al. 1995, Moraga et al. 1997). AA, which is esterified to the sn-2 position of membrane phospholipids, can be preferentially released from phospholipids by activation of PLA2. It can also be produced by activation of phospholipase C followed by diacylglycerol lipase, phospholipase D followed by phosphatidic acid phosphohydrolase and diacylglycerol lipase, and finally, PLA2 followed by lyso-phospholipase (Graber et al. 1994). Previous reports have suggested that AA mediated the positive effect of PLA2 on testosterone production in Leydig cells (Romanelli et al. 1995, Yamazaki et al. 1996), indicating that AA, in addition to cAMP, could be regulating LH–hCG–stimulated steroidogenesis. 

At present, however, mechanisms involved in the release of AA by Leydig cells are not completely understood. Previous studies have indicated a direct effect of LH (Cooke et al. 1991) and hCG (Moraga et al. 1997) on the release of AA in these cells. Specifically, our previous results demonstrated that the release of AA in hCG-treated rat Leydig cells occurred in a dose- and time-dependent manner (Moraga et al. 1997). In addition, the amount of AA released was dependent on the hormone-receptor interaction and the concentration of LH–hCG binding sites present on the cell surface (Moraga et al. 1997). Results of the present study performed in the presence of inhibitors or activators of PLA2 indicate that PLA2 could be involved in hCG-induced AA release. Two different inhibitors of PLA2 having different modes of action were used: mepacrine, which interferes with the substrate–enzyme interface, preventing the PLA2 from hydrolysing the phospholipid substrate (Chang et al. 1987), and pBpB, which binds covalently to a histidine residue on PLA2, reducing calcium binding and enzyme activity (Drent et al. 1976). Both compounds consistently inhibited the hCG–stimulated release of AA. Conversely, melittin, an activator of PLA2, increased the release of AA (Fig. 2). Melittin, a bee venom polypeptide, forms a complex with the phospholipid substrate, which appears to be closely...

**Figure 3** Effect of the PLA2 inhibitor mepacrine on the release of AA from melittin- and hCG-stimulated Leydig cells. Leydig cells ($2 \times 10^6$) were incubated with 0-2 μCi $^{14}$C AA for 4 h, then collected, centrifuged at 800 g for 10 min, and washed twice. Prelabelled Leydig cells were permeabilized with saponin (25 μg/ml) for 15 min to allow entry of GTP$\gamma$S, then incubated in DMEM–05% fatty acid-free BSA under an atmosphere of 95% air–5%CO$_2$ in the presence of mepacrine (10 μM), then incubated in the presence or absence of hCG (25 mIU) or melittin (10 μM) for 2 h. After that, total $^{14}$C AA was extracted, separated by TLC and quantified by liquid scintillation spectrometry, as indicated in Materials and Methods. $^{14}$C AA released from cells without any treatment was arbitrarily set as 100 ± S.E.M.%. Different letters indicate significantly different values ($P \leq 0.05$, mean ± S.E.M.; $n = 3$ independent experiments performed in triplicate).

**Figure 4** Effect of GTP$\gamma$S on the release of AA from Leydig cells. Leydig cells ($2 \times 10^6$) were incubated with 0-2 μCi $^{14}$C AA for 4 h, then collected, centrifuged at 800 g for 10 min, and washed twice. Prelabelled Leydig cells were permeabilized with saponin (25 μg/ml) for 15 min to allow entry of GTP$\gamma$S, then incubated in DMEM–05% fatty acid-free BSA under an atmosphere of 95% air–5%CO$_2$ in the presence of GTP$\gamma$S (100 μM), GDP (100 μM), hCG (25 mIU) or GTP$\gamma$S plus hCG for 2 h. After that, total $^{14}$C AA was extracted, separated by TLC and quantified by liquid scintillation spectrometry as indicated in Materials and Methods. $^{14}$C AA released from control cells was arbitrarily set as 100 ± S.E.M.%. Different letters indicate significantly different values ($P \leq 0.05$, mean ± S.E.M.; $n = 3$ independent experiments performed in triplicate).
linked with the ability to enhance the action of PLA₂ (Mollay & Kreil 1974). Mepacrine was able to inhibit the hCG-stimulated release of AA, but not the melittin-induced release, indicating that melittin was able to bypass the effect of mepacrine on PLA₂ (Fig. 3). A possible explanation for this unexpected result may be that, in the presence of melittin, mepacrine was unable to be affecting the lipid–water interface. Therefore, the positive effects of melittin at the interface might prevail over the negative effects of mepacrine at this level.

In Leydig cells, several reports have indicated that AA may regulate both basal and hormone-stimulated sterioidogenesis (Didolkar & Sundaram 1987, Lopez-Ruiz et al. 1992, Marinero et al. 1996). This suggests a link between intracellular release of AA and sterioidogenesis. Experiments with PLA₂ inhibitors (to inhibit the release of AA) have demonstrated an inhibition of Bt₂cAMP and LH-stimulated testosterone production in rat Leydig cells (Abayasekara et al. 1990, Cooke et al. 1991, Mele et al. 1997). Conversely, melittin, the activator of PLA₂, had positive effects on testosterone production (Mukhopadhyay et al. 1985). Although these results provide evidence for a stimulatory role of AA on sterioidogenesis, it was also shown that exogenous AA might exert a dose- and time-dependent biphasic effect on LH-stimulated Leydig cells (Lopez-Ruiz et al. 1992). In cells incubated with sub-maximal LH concentrations, AA

![Figure 5](image-url) Effect of PTX on the release of AA from Leydig cells. Leydig cells (2 × 10⁶) were incubated with 0·2 μCi [14C]AA for 4 h, then cells were collected, centrifuged at 800 g for 10 min, and washed twice. Prelabelled Leydig cells were permeabilized with saponin to allow entry of PTX, and subsequently incubated in DMEM–0·5% fatty acid-free BSA under an atmosphere of 95% air–5%CO₂ with PTX (20 ng/ml) for 40 min. hCG (25 mIU) was added to some tubes and incubation continued for an additional 2 h. After that, total [14C]AA was extracted, separated by TLC and quantified by liquid scintillation spectrometry as indicated in Materials and Methods. [14C]AA released from control cells was arbitrarily set as 100 ± s.e.m.%. Different letters indicate significantly different values (P < 0·05, mean ± s.e.m.; n = 3 independent experiments performed in triplicate).

![Figure 6](image-url) Effect of exogenous AA on cAMP production in Leydig cells. Approximately 2 × 10⁶ Leydig cells were preincubated for 30 min at 34°C with DMEM–0·1% BSA under an atmosphere of 95% air–5%CO₂, then incubated with IBMX (25 μM) and different concentrations of AA (0, 0.1, 1, 10, 50 and 100 μM) in the presence or absence of 5 mIU hCG (A) or 25 mIU hCG (B). After 3 h, cAMP was determined by RIA as described in Materials and Methods. Different letters indicate significantly different values (P < 0·05, mean ± s.e.m.; n = 3 independent experiments performed in triplicate).

The function of AA in steroidogenesis involves the regulation of the steroidogenic acute regulatory protein (StAR; Wang et al. 1999), which mediates the transfer of cholesterol to the inner mitochondrial membrane (Lin et al. 1995). Specifically, in MA–10 Leydig tumor cells, AA regulates StAR production at the level of gene transcription (Wang et al. 2000). This AA–mediated signal transduction pathway is clearly different from the reported cAMP–protein kinase A–phosphorylation pathway, the classical mechanism by which trophic hormones stimulate steroidogenesis (Wang & Stocco 1999).

In the present study, in addition to PLA$_2$, a G protein was also found to be involved in the release of AA, as GTP$_S$, a non-hydrolyzable analogue of GTP, was also able to increase AA release in permeabilized cells (Fig. 4). In the absence of hCG, exogenous GTP$_S$ stimulated similar degrees of AA release as with the hormone alone. In addition, the stimulatory effect of GTP$_S$ was not additive to that of hCG (Fig. 4). This observation suggests that hCG stimulates the release of AA through a mechanism involving activation of G proteins. In this regard, it has been shown that, after LH–hCG receptor activation, a family of G proteins present in Leydig and ovarian follicular cells membranes are activated. These G proteins include G$_{q11}$, G$_{13}$ and G$_i$ (Rajagopalan-Gupta et al. 1998). The authors postulated that activated G proteins could be related to the PLC pathway. Nevertheless, it cannot be completely ruled out that at least one of the multiple LH–hCG-activated G proteins could be related to a different effector, such as PLA$_2$. This type of interaction has previously been reported for other somatic cells (Fain et al. 1988, Axelrod et al. 1988, Chen & Chen 1998).

Experiments performed in the presence of PTX showed that this compound was able to inhibit hCG–stimulated release of AA, suggesting the involvement of a member of the Gi family in this event (Fig. 5). PTX catalyses the ADP-ribosylation of a specific cysteine residue in the Gi family, inactivating the Gi-subunits, such that they cannot exchange GDP for GTP (Nestler & Duman 1994). We therefore hypothesize that a G protein, presumably from the Gi family, may be part of the mechanism involved in the release of AA. Early studies have shown that PTX can stimulate cAMP production in Leydig cells (Platts et al. 1988). In addition, in whole testicular cells, PTX potentiated hCG-stimulated cAMP and testosterone production (Adashi et al. 1984). Nevertheless, it is worth noting that the effects reported by these authors were not observed when cells were incubated with PTX during periods of incubation less than 24 h.

In our previous work, we suggested that AA released from rat Leydig cells was independent of cAMP, because the stimulation of cAMP production and the release of AA were dependent on different hCG concentrations (Moraga et al. 1997). However, in MA–10 mouse Leydig tumor cells, Bt$_2$cAMP-induced steroid production was inhibited in the presence of PLA$_2$ inhibitors – an effect that was
reversed by the addition of exogenous AA to the medium (Wang et al. 1999, 2000). These results, although not directly, would indicate that AA release may occur downstream of cAMP production, and that cAMP could regulate PLA2 activity and the release of AA. At present, however, reported data suggest that LH–hCG-stimulated release of AA might occur either dependently or independently of cAMP (Moraga et al. 1997, Wang & Stocco 1999).

In contrast, results from the present study indicate that exogenous AA could modulate cAMP production in a manner dependent on the amount of AA and the concentration of hCG (Fig. 6). It was shown that, in the presence of 5 mIU hCG, an exogenous concentration of AA as high as 100 µM inhibits cAMP production by Leydig cells (Fig. 6A). However, in the presence of 25 mIU hCG, a lower concentration of exogenous AA (25 µM) is able to inhibit cAMP production (Fig. 6B). These results can be explained in the light of our previous findings (Moraga et al. 1997) of a clearly demonstrated dose-dependent effect of hCG on the release of AA. Higher concentrations of AA should therefore be released with 25 mIU than with 5 mIU of hCG. Thus, when Leydig cells are treated with 25 mIU hCG, 25 µM exogenous AA will be sufficient to contribute to attaining a total amount of AA (entry of exogenous AA+intracellular AA released by hCG) that is able to modulate cAMP production. Conversely, lower concentrations of intracellular AA will be released in the presence of 5 mIU hCG, therefore more exogenous AA (100 µM) will be required to reach the necessary total amount of AA needed to modulate cAMP. These findings are in accordance with results shown in Fig. 7, where it can be observed that, in the presence of PLA2 inhibitors, cAMP production was not modified. Under these conditions, concentrations of AA released were similar to those found in untreated cells (Fig. 1), and therefore not sufficient to modulate the hCG-stimulated cAMP. The inhibitory effect of AA on cAMP production in Leydig cells has been described before (Marinero et al. 1996). These authors demonstrated that AA inhibited, in a dose-dependent manner, LH-induced cAMP and testosterone production. In addition, they concluded that AA maintained G proteins in their activated state, which in turn inhibited adenylate cyclase and decreased cAMP concentrations (Marinero et al. 2000).

Our results and others from the literature provide evidence that attainment of an intracellular AA concentration able to modulate cAMP clearly depends on exogenously added fatty acid. Nevertheless, we would like to speculate that, inside a hormonally stimulated Leydig cell, AA may reach a transient concentration high enough to modulate cAMP in a specific confined location, and thus may constitute a physiologically relevant event. This kind of compartmentalization might be similar to that reported for cAMP (Dufau 1988). All these results indicate that both pathways, albeit independent, are related, and suggest that modulation of intracellular concentrations of cAMP could constitute one of the rapid non-genomic actions of the AA released in response to the hormonal stimulus.

As AA and cAMP are essential for maximal steroidogenesis, neither pathway alone being sufficient for trophic hormone–induced steroid production, the finding that AA was able to inhibit cAMP production could be considered contradictory. However, it has long been recognized that very small increases in intracellular cAMP, not necessarily detected under typical experimental conditions, are sufficient to trigger maximal steroidogenic responses (Catt & Dufau 1973). Thus the regulatory effect of AA on cAMP production not only does not impair optimal steroid production, but also helps to co-regulate optimal concentrations of both messengers, when needed inside the cell to assure the steroidogenic function.

In summary, results presented in this study provide evidence to suggest that, in Leydig cells: (1) PLA2 is involved in the release of AA stimulated by hCG; (2) a G protein from the PTX-sensitive family is involved in PLA2-mediated AA release, and (3) AA may be involved in the regulation of cAMP production.

Collectively, our present and previous results (Moraga et al. 1997), and those reported in the literature (Axelrod et al. 1988, Marinero et al. 1996, 2000, Wang et al. 1999, 2000), lead us to suggest the following mechanism of LH–hCG action in Leydig cells. The LH–hCG–receptor interaction promotes the release of AA through the activation of a G protein, presumably a Gs, which in turn activates PLA2 activity and releases AA from membrane phospholipids. AA then acts at the plasma membrane level, possibly by activation of additional G proteins (Gi) involved in adenylate cyclase inhibition, and thus decreases cAMP production. Alternatively, the LH–hCG–receptor complex could be simultaneously coupled to different G protein families, modulating both the adenylate cyclase and PLA2 activities. These events could be occurring synchronously at different plasma membrane microdomains, after hormone–receptor interaction. Thus each intracellular signal, cAMP or AA, could temporarily modify the concentration of the other, constituting a transient and spatially confined cross-talk between the two molecules. This interaction would allow a co-ordinated and regulated biological response at different levels, leading to optimal steroidogenesis in Leydig cells.

Acknowledgements

We thank the NIHPP program for the supply of hCG and Drs I Atwater and B Andrews for critical reading of this manuscript. The technical assistance of Miss Natalia Cisterna is greatly acknowledged. This study was supported by Fondo Nacional de Ciencia y Tecnologia de Chile, Grant FONDECYT No. 1940544 to A M R.
References


Received 7 September 2001
Accepted 19 September 2001